In vitro analysis of the antileukemic effect of tumor necrosis factor-α gene therapy with myeloid progenitor cells: The role of dendritic cells

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 2, 2003, Pages 62-71

  Xu, Yong X ^a   Deeb, Dorrah ^a   Gao, Xiaohua ^a   Janakiraman, Nalini ^a   Chapman, Robert A ^a   Gautam, Subhash C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Dendritic cells; Gene therapy; Hematopoietic progenitors; Leukemia; TNF

Indexed keywords

ANTILEUKEMIC AGENT; CD40 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE THERAPY; GENETIC TRANSDUCTION; LEUKEMIA; LEUKEMIA CELL; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION; SPLEEN CELL; TRANSGENE;

ANIMALS; ANTIGENS, CD11C; BONE MARROW CELLS; CELL LINE; DENDRITIC CELLS; FLOW CYTOMETRY; GENE THERAPY; INTERLEUKIN-12; LEUKEMIA; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MYELOID PROGENITOR CELLS; PHENOTYPE; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; THYMIDINE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0037777760     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2003.01069.x     Document Type: Article

References (45)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 271-96, 1991.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392: 245-52, 1998.
3. Koch F, Trockenbacher B, Kampgen E, et al. Antigen processing in populations of mature murine dendritic cells is caused by subsets of incompletely matured cells. J Immunol 155: 93-100, 1995.
4. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation. Adv Exp Med Biol 417: 1-6, 1997.
5. Rescigno M, Winzler C, Delia D, et al. Dendritic cell maturation is required for initiation of the immune response. J Leukoc Biol 61: 415-42, 1997.
6. Austyn JM, Kupiec-Weglinski JW, Hankins DF, et al. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. J Exp Med 167: 646-51, 1988.
7. Austyn JM. Antigen uptake and presentation by dendritic leukocytes. Semin Immunol 4: 227-36, 1992.
8. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9: 10-6, 1997.
9. Roake JA, Rao AS, Morris PJ, et al. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 181: 2237-47, 1995.
10. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate maturation of epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 167: 700-12, 1988.
11. Cella M, Engering A, Pinet V, et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388: 782-78, 1997.
12. Lutz MB, Girolomoni G, Ricciardi-Castagnoli P. The role of cytokines in functional regulation and differentiation of dendritic cells. Immunobiology 195: 431-55, 1995.
13. Inaba K, Witmer-Pack M, Inaba M, et al. The tissue distribution of the B7-2 co-stimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 180: 1849-60, 1994.
14. Inaba K, Pack M, Inaba M, et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 186: 665-72, 1997.
15. + T cells. J Immunol 154: 5071-9, 1995.
16. Heufler C, Koch F, Stanzl U, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-γ production by T helper 1 cells. Eur J Immunol 26: 659-68, 1996.
17. Celluzzi C, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 183: 283-7, 1996.
18. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone-marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1:1297-302, 1995.
19. Paglia P, Chiodoni, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183: 317-22, 1996.
20. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95: 9482-7, 1998.
21. Shimizu K, Thomas EK, Giedlin M, et al. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 61: 2618-24, 2001.
22. Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-72, 1996.
23. Condon C, Watkins SC, Celluzzi CM, et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2: 1122-8, 1996.
24. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-8, 1995.
25. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of myeloma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 3: 328-32, 1998.
26. Warren SJ, Ward PA, Johnson KJ. Tumor necrosis factor: a plurifunctional mediator of acute inflammation. Mod Pathol 1: 242-7, 1988.
27. Grunfeld C, Palladino MA. Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. Adv Intern Med 35: 45-71, 1990.
28. Sugarman BJ, Aggarwal B, Hass PE, et al. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-5, 1985.
29. Asher A, Mule J, Reichert ES, et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-74, 1987.
30. Haranaka K, Santonai N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34: 263-7, 1984.
31. Sherman M, Spriggs D, Arthur K, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: a phase 1 toxicity and effects on lipid metabolism. J Clin Oncol 6: 344-50, 1988.
32. Spriggs D, Shemman M, Michie H, et al. Recombinant human tumor factor administered as a 24-hour intravenous infusion: a phase 1 and pharmacologic study. J Natl Cancer Inst 80: 1039-44, 1988.
33. Gautam SC, Pindolia KR, Xu YX, et al. Antileukemic activity of TNF-α gene therapy with myeloid progenitor cells against minimal leukemia. J Hematother 7: 115-25, 1998.
34. Gautam SC, Xu YX, Pindolia KR, et al. TNF-α gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-α therapy. J Hematother 8: 237-45, 1999.
35. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-702, 1992.
36. Cella M, Salio M, Sakakibara Y, et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 189: 821-9, 1999.
37. + T cells in vitro. Blood 91: 4652-61, 1998.
38. Josien R, Li H-L, Ingulli E, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191: 495-501, 2000.
39. Morel Y, Truneh A, Sweet RW, et al. The TNF superfamily LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 167: 2479-86, 2001.
40. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α. J Exp Med 179: 1109-18, 1994.
41. Ludeuig B, Graf B, Gelderblom HR, et al. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNFα, but strongly enhanced by interleukin-10. Eur J Immunol 25: 1943-50, 1995.
42. Grabbe S, Bruvers S, Lindgren AM, et al. Tumor antigen presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and ultraviolet radiation. J Leukoc Biol 52: 209-17, 1992.
43. Trevejo JM, Marino MW, et al. TNF-α-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc Natl Acad Sci USA 98:12162-7, 2001.
44. Brunner C, Seiderer J, Schlamp A, et al. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic antitumor immune responses in vivo. J Immunol 165: 6278-86, 2000.
45. Paczesny S, Beranger S, Salzmann J-L, et al. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 61: 2386-9, 2001.